S3840 Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2

Billable / valid for submission HCPCS Release 2026Q3

Short description: Dna analysis ret-oncogene

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2	yes

S3800 Genetic testing for amyotrophic lateral sclerosis (als)
S3841 Genetic testing for retinoblastoma
S3842 Genetic testing for von hippel-lindau disease
S3844 Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
S3845 Genetic testing for alpha-thalassemia
S3846 Genetic testing for hemoglobin e beta-thalassemia
S3849 Genetic testing for niemann-pick disease
S3850 Genetic testing for sickle cell anemia
S3852 Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease
S3853 Genetic testing for myotonic muscular dystrophy
S3854 Gene expression profiling panel for use in the management of breast cancer treatment
S3861 Genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome
S3865 Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
S3866 Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (hcm) in an individual with a known hcm mutation in the family
S3870 Comparative genomic hybridization (cgh) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability